At present, the results of listed companies in the first half of 2022 have been basically disclosed, and 449 pharmaceutical companies have handed over their report cards
.
Among them, the research and development expenses of traditional Chinese medicine enterprises have become the focus
of attention of many people in the industry.
According to statistics, the total R&D expenditure of 73 A-share Chinese medicine enterprises in the first half of the year exceeded 4 billion yuan, and more than 70% increased
year-on-year.
Among them, 12 companies such as Tibet Pharmaceutical, Zuoli Pharmaceutical and Huluwa increased by more than 50% year-on-year; The R&D expenditure of Tasly and Yiling Pharmaceutical exceeded 200 million yuan
.
Tasly
Tasly
In the first half of the year, during the reporting period, Tasly's R&D expenses were RMB465.
6184 million, an increase of 81.
66%
over the same period last year.
Excluding the impact of the significant increase in the Company's R&D expenses, which was due to the licensing fees of Sutro Biopharma and Inc.
, R&D expenses increased by approximately 169%
year-on-year.
Benefiting from the continuous increase in innovation investment, Tasly currently has 92 research projects, of which 45 are Class 1 innovative drug projects, and 43 projects have entered the clinical stage
.
In addition, among the existing pipelines, there are 47 independent research and development projects, 21 product introduction projects, 16 cooperative development projects, and 8 investment priority licensing projects
.
Among them, there are 20 pipelines in the field of cardiovascular and cerebrovascular research; 16 in the field of digestion and metabolism; 22 oncology fields; 26 pipelines of traditional Chinese medicine under research; 16 biological drugs; 46 chemical drugs
.
Baiyun Mountain
Baiyun Mountain
In the first half of this year, the research and development cost of Baiyun Mountain reached 441.
319 million yuan
.
In recent years, Baiyun Mountain is seeking development with innovation, and from 2017 to 2021, its research and development expenses will be 373 million yuan, 585 million yuan, 577 million yuan, 612 million yuan and 875 million yuan, respectively, with a total of 3 billion yuan
.
At present, Baiyun Mountain is actively promoting the research and development of biomedical drugs, and strives to further enrich the company's product categories
in the Danan medicine sector.
It said that in the future, the company will continue to increase investment in research and development, continue to promote innovative drug research and development, generic drug development, secondary development of listed drugs, etc.
, strengthen the cultivation of new products, and promote the continuous innovation and development of
the company's southern medicine sector.
In addition, it will also focus on the development of medical services, traditional Chinese medicine health, modern pension three major areas and medical equipment industry
.
To Ling Pharmaceutical
To Ling Pharmaceutical
In the first half of 2022, Yiling Pharmaceutical's R&D investment was 374 million yuan, accounting for 4.
03% of operating income, which was at the forefront of
the same industry.
It is understood that in the first quarter of 2021, its research and development expenses have reached 188 million yuan, an increase of 68.
32%
year-on-year.
At present, Yiling Pharmaceutical adheres to the innovation development strategy driven by science and technology, and has formed a scientific and technological core competitiveness
with the advantage of guiding the treatment of clinical major diseases and respiratory infectious diseases with the theory of network disease, and the innovation of network disease theory drives the research and development of patented new drugs.
It has developed 13 new patented new drugs on the market, and a number of traditional Chinese medicine products are in the research and development stage, such as Pediatric Lianhua Qinggan Granules have completed the clinical phase II clinical trial, Chai Qiantong Lensing tablets new indications of drug clinical trial approval notice, old products Yangzheng Elimination Capsules are applying for new indications
.
These drugs cover cardiovascular and cerebrovascular diseases, respiratory diseases, diabetes, tumors and other clinical multiple and major disease areas, forming a relatively rich array of products, which is expected to provide strong impetus and steady support
for the sustained and stable growth of the company's sales revenue and profits in the future.
Kangyuan Pharmaceutical
Kangyuan Pharmaceutical
On the evening of August 1, Kangyuan Pharmaceutical disclosed the semi-annual performance report of 2022, and the performance data of the first half of this year continued the growth trend of 2021, achieving a total revenue of 2.
097 billion yuan, an increase of 18.
54% year-on-year; The net profit attributable to the shareholders of the listed company was 211 million yuan, an increase of 32.
35%
year-on-year.
Among them, in terms of R&D investment, the R&D expenditure of Kangyuan Pharmaceutical reached 277 million yuan, an increase of 28.
01%
year-on-year.
It is worth mentioning that in the first half of the year, under the background of the growth of R&D investment, Kangyuan Pharmaceutical accelerated the establishment and research and development of pediatric, cardiovascular, elderly and metabolic disease drugs, expanded new clinical fields, and strengthened the research on
the cultivation of key medical insurance or basic drugs in traditional Chinese medicine.
CR 39
CR 39
According to the 2022 semi-annual report, CR Sanjiu invested 215 million yuan in research and development in the first half of 2022, and the company's key research projects are progressing normally
.
Among them, Class 1 innovative Chinese medicine DZQE is promoting Phase II clinical preparations; Phase 1 clinical trial of Class 1 small molecule targeted antitumor drug QBH-196 is underway; The new drug ONC201 for H3K27M mutant glioma is actively promoting domestic registration and application
.
Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.
